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Abstract Two transgenic mouse lines expressing an
inducible form of the Cre recombinase (CreERTM)
under the control of the human GFAP promoter have
been generated and characterized. In adult mice,
expression of the fusion protein is largely confined to
astrocytes in all regions of the central nervous
system. Minimal spontaneous Cre activity was
detected and recombination was efficiently induced
by intraperitoneal administration of tamoxifen in
adult mice. The pattern of recombination closely
mirrored that of transgene expression. The percentage
of astrocytes undergoing recombination varied from
region to region ranging from 35% to 70% while a
much smaller portion (\1%) of oligodendrocytes and
neural precursor cells showed evidence of Cre
activity. These mouse lines will provide important
tools to dissect gene function in glial cells and in
gliomagenesis.
Keywords Cre  Inducible recombination 
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Introduction
Astrocytes are the most abundant glial cell type in the
mammalian brain and play important roles in all
aspects of the developing and mature organ (He and
Sun 2007). This includes, but is not restricted to a
housekeeping function in support of neurons, the
establishment and maintenance of the blood-brain
barrier and the regulation of synaptogenesis and
synaptic plasticity. It is perhaps not surprising then,
that astrocytes are proposed to be at the root of
numerous pathological processes such as glial scar-
ring following brain injuries, Alexander disease and
the most common primary brain tumor, glioma (He
and Sun 2007). The availability of the appropriate
molecular tools to manipulate gene expression
in vivo is therefore critical to further our understand-
ing of astrocyte contributions to normal and disease
states.
A large number of brain-specific bacteriophage P1
Cre recombinase-expressing mouse strains have been
developed, including those using the glial fibrillary
acidic protein (GFAP) promoter to drive astrocyte-
specific expression of cre (Gaveriaux-Ruff and Kief-
fer 2007). The expression pattern directed by the
GFAP promoter in transgenic mice has been exten-
sively studied and mapped (Brenner and Messing
1996; Johnson et al. 1995). In adult mice its activity
is restricted predominantly to astrocytes while
embryonic expression targets neural precursor cells
of the ventricular zone and spinal cord. In addition, a
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subset of Gfap-expressing glial cells located in the
subventricular zone of the adult brain have been
shown to function as adult neural stem cells capable
of giving rise to the major cell types in the brain:
mature astrocytes, oligodendrocytes and neurons
(Doetsch 2003). Because Cre-mediated recombina-
tion is irreversible, embryonic expression in neural
precursor cells directed by the GFAP promoter and/or
aberrant expression resulting from transgene insertion
effects have resulted in substantial Cre-mediated
recombination in mature neurons as well as glial cells
in all GFAP-cre mice characterized to date (Bajenaru
et al. 2002; Casper and McCarthy 2006; Fraser et al.
2004; Kwon et al. 2001; Marino et al. 2000; McCarty
et al. 2005; Zhuo et al. 2001). Therefore, the ability
to restrict Cre activity during embryogenesis could
greatly mitigate neuronal Cre-mediated recombina-
tion in GFAP-Cre mice and allow for the study of
gene function in mature astrocytes without disruption
of function in neurons.
Cre activity can be regulated in a temporal fashion
by engineering a fusion protein with the ligand
binding domain of a steroid hormone receptor, such
as the estrogen receptor (Feil et al. 1996; Hayashi and
McMahon 2002). Furthermore, a specific point
mutation within the ligand-binding domain termed
ERTM abolishes the binding to endogenous steroid
hormones while retaining its interaction with syn-
thetic estrogen analogs such as tamoxifen. The fusion
protein, CreERTM, is inactive while sequestered in
the cytoplasm by heat shock protein complexes.
Binding of tamoxifen releases CreERTM from this
complex allowing ligand-dependent translocation to
the nucleus where the fusion protein is active and
directs recombination between loxP sites (Hayashi
and McMahon 2002). In this report, we describe the
characterization of two mouse strains expressing
the CreERTM fusion protein under the control of the
human GFAP promoter.
Materials and methods
Transgenic and reporter mice
Standard subcloning techniques were used to con-
struct the transgene placing the 2.2 Kb human GFAP
promoter (a gift from D. Gutmann) (Brenner et al.
1994) upstream of the cDNA encoding the CreERTM
fusion protein (provided by A. McMahon). This was
followed by an internal ribosomal entry sequence
(IRES) and the cDNA encoding bacterial b-galacto-
sidase (b-gal) to facilitate detection of transgene
expression. The construct was terminated by an SV40
intronic sequence and polyadenylation signal. Fol-
lowing pronuclear injection into fertilized FVB/NJ
oocytes and implantation into foster mothers, the
transgenic founder was identified by polymerase
chain reaction (PCR) with primers recognizing the
Cre sequence (50 AGCGATCGCTGCCAGGAT 30
and 50 ACCAGCGTTTTCGTTCTGCC 30). Integra-
tion of the transgene was confirmed by Southern blot
using a probe recognizing the SV40 sequences. The
mouse line was propagated by crossing with FVB/NJ
wild-type mice. Cre activity was assessed by crossing
into the Z/EG reporter mouse line (Jackson Labora-
tory, Bar Harbor, ME) (Novak et al. 2000). Reporter
positive mice were identified by PCR using primers
to the GFP gene (50 CCGGGGTGGTGCCCATCC
TGGT 30 and 50 GCTCCTGGACGTAGCCTTCGG
GC 30). All experiments involving mice were carried
out in compliance with the Animal Care and Use
Committee at St. Jude Children’s Research Hospital.
Induction of Cre activity
Tamoxifen (Sigma, St. Louis, MO) was dissolved in
corn oil (Sigma) at a concentration of 20 mg/ml at
37C, and then filter sterilized and stored for up to
7 days at 4C in the dark. A 27 g needle tuberculin
syringe (Becton Dickinson, Franklin Lakes, NJ) was
used for intraperitoneal injections at the indicated
doses. An equivalent volume of sterile filtered corn
oil alone was used for vehicle injections. Multiple
injections in the same mouse were separated by 24 h.
Histochemistry
Animals were perfused with 19 phosphate-buffered
saline (PBS) followed by 2% paraformaldehyde (PFA)
in PBS. Following dissection, tissues were post-fixed
overnight in 2% PFA in PBS at 4C, and then
equilibrated to 25% sucrose in PBS for a further 24 h
at 4C. Tissues were subsequently embedded and
cryosectioned at a thickness of 12 lm. Tissue slides
were washed three times in PBS prior to staining.
For detection of b-gal activity, slides were washed
in Rinse A (100 mM NaPO4, pH 7.3; 2 mM MgCl2;
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Fig. 1 Generation of transgenic mouse lines. (a) Diagram of
transgenic construct. The 2.2 Kb human GFAP promoter
drives expression of cDNAs encoding the Cre-estrogen
receptor ligand binding domain (CreERTM) fusion protein, an
internal ribosome entry site (IRES) and E. coli b-galactosidase
(b-gal). (b) Southern blot. Genomic DNAs from the transgenic
founder mouse and a panel of F1 progeny were digested with
EcoRI (location of restriction sites within the transgene are
indicated in panel (a)) to detect fragments resulting from
internal digest of the multicopy transgene as well as those
containing the junction of the transgene with the insertion sites
in genomic DNA. The fragments corresponding to the insertion
site for GFAP-CreERTMA (arrowhead) and for GFAP-
CreERTMB (arrow) are shown. The probe was directed against
SV40 sequences as indicated in panel (a)
Fig. 2 Transgene expression analysis of adult GFAP-
CreERTM brains by b-gal histochemistry. (a–e) GFAP-
CreERTMA brain. (f–j) GFAP-CreERTMB brain. (a, f) Sagittal
sections of brain. Scale bar in (a) is 1 mm and applies to (f).
(b, c, g, h) Sagittal sections of cerebellum at low (b, g) and
high (c, h) power. The arrows in (c) and (h) indicate the
location of Bergman glia. Scale bar in (b) is 0.5 mm and
applies to (g) and that in (c) is 50 lm and applies to (h). (d, i)
Sagittal sections through dentate gyrus. The arrows indicate the
inner layer of the dentate gyrus, the location of neural
progenitor cells. Scale bar in (d) is 100 lm and applies to
(i). (e, j) Sagittal sections through subventricular zone. The
arrows indicate a transgene-expressing cell in the subventric-
ular zone. Scale bar in (e) is 10 lm and applies to (j)
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5 mM EGTA) for 30 min followed by Rinse B
(100 mM NaPO4 pH 7.3; 2 mM MgCl2; 0.01%
sodium deoxycholate; 0.02% NP-40) for 5 min.
Slides were then stained at 37C for 3–4 days in
Developing Buffer (1 mg/ml X-gal; 100 mM NaPO4;
pH 7.3; 2 mM MgCl2; 0.01% sodium deoxycholate;
0.02% NP-40; 5 mM K3Fe(CN)6; 5 mM K4Fe(CN)6).
After washing extensively in PBS, slides were
counterstained with Nuclear Fast Red (Vector Labs,
Burlingame, CA).
Immunohistochemistry and immunofluorescence
Cryosections were prepared as above. Primary anti-
bodies used for immunodetection were against GFP
(1:5000 for immunohistochemistry, 1:500 for immu-
nofluorescence; Molecular Probes, Eugene, OR),
S100b (1:200; Sigma), NeuN (1:500; Chemicon,
Temecula, CA), CC-1 (1:50; Calbiochem, San Diego,
CA), Gfap (1:200; Sigma) and S100 (1:500; Dako,
Carpinteria, CA). Microwave antigen retrieval was
performed for all antibodies except anti-GFP. For
immunohistochemistry, biotinylated secondary anti-
bodies were used in conjunction with horseradish
peroxidase-conjugated streptavidin (Elite ABC, Vec-
tor Laboratories) treated with NovoRed or VIP
(Fig. 5) substrate (Vector Laboratories) and counter-
stained with hematoxylin or methyl green (Vector
Laboratories), respectively. For immunofluorescence,
Alexa Fluor 488 (Molecular Probes) and cyanine 3
(Jackson Immunoresearch, West Grove, PA) conju-
gated secondary antibodies were employed along
with Vectashield mounting media containing 40,6-
diamino-2-phenylindole (Vector Laboratories).
Quantitation
The percentage of astrocytes undergoing Cre-medi-
ated recombination was determined in five GFAP-
CreERTMA; Z/EG mice injected with 9 mg/40 g body
Fig. 3 Cre-mediated recombination in adult brains by immu-
nohistochemistry for GFP reporter. (a–c) Z/EG single
transgenic mouse injected with 9 mg/40 g tamoxifen daily
for 5 days. (d–f) GFAP-CreERTMA; Z/EG double transgenice
mouse injected with vehicle daily for 5 days. Inset represents
images from an uninduced 14-month-old double transgenic
mouse whereas all other mice presented are *8 weeks of age
as indicated in the text. (g–i) GFAP-CreERTMA; Z/EG double
transgenic mouse injected with 9 mg/40 g tamoxifen daily for
5 days. Brain regions presented are sagittal sections through
the cerebellum (panels a, d, g), cerebral cortex and hippocam-
pus (panels b, e, h) and thalamus and hypothalamus (panels c,
f, i). Scale bar is 0.5 mm and applies to all panels
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weight tamoxifen daily for 5 days. Serial cryosec-
tions were stained with S100 and GFP and positively
stained cells (identified by visibly stained nucleus)
from equivalent surface areas in various regions of
the brain were counted with the aid of the Bioquant
system (Bioquant Image Analysis Corp., Nashville,
TN). The average number of cells counted in each
mouse for the cerebellum, cortex, hippocampus and
thalamus/hypothalamus was 1260, 1430, 490, and
2500, respectively. For oligodendrocytes, CC-1
positive cells in the corpus callosum of cryosections
from two brains were counted (3220 cells each) and
compared to the number of double positive CC-1 and
GFP staining cells in an adjacent section. The total
number of subventricular zone nuclei in sections from
four different animals was determined (an average of
2260 nuclei per mouse) and compared to the number
of GFP positive cells in the same sections.
Results
The cDNA encoding the CreERTM fusion protein was
placed downstream of the 2.2 Kb human GFAP
promoter (Fig. 1a) (Brenner et al. 1994). This was
followed by an internal ribosomal entry site (IRES)
and a LacZ cDNA encoding a nuclear-targeted
version of E. coli b-galactosidase (b-gal). The con-
struct was terminated by an SV40 large T intron and
polyadenylation signal. After pronuclear injection of
FVB/NJ eggs, one founder was obtained. Transgene
integration in this line, hereafter termed GFAP-
CreERTM, was verified by polymerase chain reaction
(PCR) for Cre-specific sequences as well as by
Southern blot hybridization (Fig. 1b). The latter
result suggested the presence of two independent
integration sites, a conclusion which was supported
by a frequency of Cre-positive F1 progeny of 76%
(63 Cre-positive out of 83 total pups). After several
rounds of breeding to wild-type FVB mice, the two
integration sites were separated into independent
lines (GFAP-CreERTMA; Fig. 1b, lanes 6–8, and
GFAP-CreERTMB; Fig. 1b, lanes 3–5). Furthermore,
a single integration site in each line was verified by
fluorescence in situ hybridization (FISH) for the
transgene in MEF cells generated from each GFAP-
CreERTM mouse line with chromosomal location of
9A5 for line A and 15E3 for line B (data not shown).
Transgene expression was characterized by histo-
chemistry for b-gal activity in adult mouse brains. In
wild-type mice, occasional histochemical staining was






GFP. Mice were treated
with tamoxifen as in Fig. 3.
(a) Cerebral cortex. The
stellate appearance of a
cortical GFP-stained cell
resembling an astrocyte is
presented. (b) Dentate
gyrus. The arrow indicates a
GFP-stained cell located in
the inner layer of the
dentate gyrus which may




self-renewing B cells of the
subventricular zone. (d)
Corpus callosum. Scale bar
in (a) is 10 lm and applies
to panels (a, c, d). Scale bar
in (b) is 50 lm
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endogenous b-gal activity (data not shown) (Chow
et al. 2006). In contrast, GFAP-CreERTM brains
exhibited specific and reproducible patterns of b-gal
activity that were virtually identical between the two
mouse lines. Cells expressing b-gal were scattered
throughout all regions of the brain (Fig. 2a, f),
however, the specific pattern in certain areas was
notable. In the cerebellum, many b-gal positive cell
bodies aligned along the Purkinje cell layer with
cellular processes extending into the molecular layer
(Fig. 2b, c arrows, g, h, arrows), a morphological
feature consistent with Bergmann glia. In the dentate
gyrus, b-gal positive cells tended to cluster in the inner
layer of this structure (Fig. 2d, i arrows) where neural
precursor cells are known to reside (Doetsch 2003).
Histochemical staining for b-gal activity was also
noted in cells of the subventricular zone surrounding
the lateral ventricle (Fig. 2e, j arrows) where Gfap-
expressing adult neural stem cells have also been
identified (Doetsch 2003). No b-gal activity was
detected in a panel of tissues from GFAP-CreERTM
adult mice including muscle, skin, lung, thymus, heart,
liver, spleen, adrenal gland, pancreas, bladder, uterus,
ovary and epididymus (data not shown). b-gal activity
was detected in the gastrointestinal tract, kidney and
testis however this likely represents endogenous
activity as similar staining was also noted in non-
transgenic control animals (data not shown).
Reporter mice were used to assess the activity of the
CreERTM fusion protein following treatment with
tamoxifen or vehicle. GFAP-CreERTM mice were
crossed with Z/EG reporter mice in which the cDNA
encoding enhanced green fluorescent protein (GFP) is
expressed only after Cre-mediated excision of a LoxP-
flanked stop cassette (Novak et al. 2000). Mice were
injected starting at 40–50 days of age intraperitoneally
with tamoxifen at a dose of 9 mg/40 g body weight or
vehicle alone daily for five injections, then sacrificed at
least 5 days after the last injection and tissues analyzed
by immunohistochemistry for GFP. In single trans-
genic mice (either GFAP-CreERTM or Z/EG alone), no
GFP immunoreactivity was detected in the brain
Fig. 5 Cre-mediated recombination in adult GFAP-
CreERTMB; Z/EG brains by immunohistochemistry for GFP.
Mice were treated with tamoxifen as in Fig. 3. (a–c) GFAP-
CreERTMB; Z/EG double transgenice mouse injected with
vehicle daily for 5 days. (d–f) GFAP-CreERTMB; Z/EG double
transgenic mouse injected with 9 mg/40 g tamoxifen daily for
5 days. Brain regions presented are sagittal sections through
the cerebellum (panels a, d), cerebral cortex and hippocampus
(panels b, e) and thalamus and hypothalamus (panels c, f).
Scale bar in (a) is 0.5 mm and applies to panels (a–f). (g) High
power image of GFP-positive cell in the cerebral cortex. (h)
Dentate gyrus. The arrow indicates a GFP-stained cell located
in the inner layer of the dentate gyrus. (i) Subventricular zone.
(j) Corpus callosum. Scale bar in (g) is 10 lm and applies to
panels (g, i, j). Scale bar in (h) is 50 lm
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(Fig. 3a–c and data not shown). In double transgenic
mice injected with vehicle, occasional GFP positive
cells were present, particularly in cerebellar Bergmann
glia (Figs. 3d–f and 5a–c). This tamoxifen-indepen-
dent Cre-mediated recombination accumulated slowly
over the period of 14 months remaining predominantly
localized to Bergmann glial cells (Fig. 3d, e insets) and
represents the ‘‘leakiness’’ of this inducible Cre strain.
In contrast, tamoxifen-injected mice displayed wide-
spread GFP expression mirroring the pattern of b-gal
activity in GFAP-CreERTM single transgenic mice
(Figs. 3g–i and 5d–f). Under higher magnification, the
cortical staining pattern for GFP revealed cells exhib-
iting a stellate morphology consistent with mature
astrocytes (Figs. 4a and 5g). Furthermore, GFP-
expressing cells were detected in the inner layer of
the dentate gyrus (Figs. 4b and 5h arrows) and in the
subventricular zone (Figs. 4c and 5i) consistent with b-
gal activity (Fig. 2d, e, i, j). GFP-expressing cells were
also noted in the corpus callosum (Figs. 4d and 5j).
To confirm the cell types targeted for Cre activity,
double labeling by immunofluorescence was per-
formed. The majority of GFP-labeled cells in all
regions of the brain were found to co-express S100b, a
marker for glial cells (Fig. 6a–c). In contrast, almost no
GFP-labeled cells co-expressed NeuN, a marker of
mature neurons (Fig. 6d–f), although the occasional
double-labeled granule neuron in the dentate gyrus,
was noted (Fig. 6f arrow). It is possible that such
cells were Gfap-expressing neural precursors when
tamoxifen was administered, then subsequently differ-
entiated into granule neurons during the 5–10-day-
period prior to analysis. Alternatively, this transgenic
line may drive CreER expression in the rare mature
granule neuron. However, immunophenotypical anal-
yses of multiple GFAP-CreERTM single transgenic
mice failed to identify any CreER expression in
neurons (data not shown). GFP-expressing oligoden-
drocytes in the corpus callosum were identified by co-
expression of the CC-1 antigen (Fig. 6g). Confocal
microscopy was used to confirm Cre activity in
occasional Gfap positive neural precursor cells of the
subventricular zone (Fig. 7).
The degree of Cre-mediated recombination was
assessed by examining sections serially stained for
S100 and GFP proteins in various regions of the brain
(Table 1). Overall, astrocyte recombination ranged
from 35% to 70% and was more efficient in the
cerebellar Bergmann glia than in other parts of the
brain. Interestingly, \1% of all cells in the subven-
tricular zone showed cre-mediated recombination
under the experimental conditions tested and proba-
bly represent Cre activity in the Gfap-expressing B
cells (Fig 7) (Doetsch 2003). This population has
been reported to comprise 20–25% of cells in the
subventricular zone (Doetsch et al. 1997). Increasing
Fig. 6 Identification of cells undergoing Cre-mediated recom-
bination in adult GFAP-CreERTMA; Z/EG brains by double
immunofluorescence. Mice were treated with tamoxifen as in
Fig. 3. (a–c) Staining with an astrocyte marker and anti-GFP.
Co-immunodetection of S100b (green) and GFP (red) is
demonstrated in the cerebellum (a), cerebral cortex (b) and
dentate gyrus (c). (d–f) Staining with a neuronal marker and
anti-GFP. There is no co-immunodetection of NeuN (green)
and GFP (red) in cerebellum (d) and cortex (e) while
occasional granule neurons of the dentate gyrus (f) express
both markers (arrow). (g) Staining with an oligodendrocyte
marker and anti-GFP. Cells staining with both CC-1 (green)
and GFP (red) were readily identified in the corpus callosum.
Scale bar in (f) is 50 lm and applies to panels (a–f). Scale bar
in (g) is 20 lm. DAPI: 40,6-diamino-2-phenylindole (blue).
Immunophenotyping results were identical in the GFAP-
CreERTMB line (data not shown)
Transgenic Res (2008) 17:919–928 925
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the dose of tamoxifen administered did not result in
further elevations in the number of GFP positive cells
(data not shown), however, recombination could be
restricted to fewer astrocytes by titrating the drug
dose from 9 to 1 mg/40 g body weight in a single
injection (Fig. 8).
Discussion
The GFAP-CreERTM mouse lines described in this
report represent useful tools for investigators inter-
ested in studying the effects of gene manipulation in
mature astrocytes. Virtually no Cre activity is present
in neurons, specifically in the cortex, allowing for the
study of cell autonomous phenomena in this cell
population. This may be particularly relevant to the
fields of brain injury and repair as well as to
gliomagenesis. Furthermore, the presence of detect-
able Cre activity in a subset of adult neural precursor
cells in the dentate gyrus and the subventricular zone
may also facilitate the study of regenerative and
oncogenic potentials of this increasingly scrutinized
cell population.
Recently, similar transgenic mouse lines have been
reported in which the CreERT2 fusion protein (Indra
et al. 1999) was expressed under the control of the
identical GFAP promoter (Casper et al. 2007; Ganat
et al. 2006; Hirrlinger et al. 2006). One report
described CreER activity in young (five-day-old) mice
and found that neural precursor cells were significantly
targeted at this age (Ganat et al. 2006). Interestingly,
these cells went on to differentiate into mature neurons,
oligodendrocytes and astrocytes in vivo taking resi-
dence in all regions of the brain. We have yet to
examine CreER activity in our juvenile mice. Two
other groups have documented CreER activity in adult
astrocytes (Casper et al. 2007; Hirrlinger et al. 2006).
One line appears to have broad activity in astrocytes,
although quantitation was not reported (Casper et al.
2007), while the other is more restricted to certain
regions of the brain (Hirrlinger et al. 2006). Neither
group commented on CreER activity in adult neural
precursor cells. Other astrocyte-specific inducible Cre
mouse strains have also been described with activity in
adult neural progenitor cells (Mori et al. 2006; Slezak
et al. 2007). We describe CreER activity in a broad
range of adult astrocytes as well as in a restricted
Fig. 7 Confocal imaging of subventricular zone in adult GFAP-
CreERTMA; Z/EG brains. Mice were treated with tamoxifen as in
Fig. 3. (a, b) Staining with antibodies against Gfap (green) and
GFP (red) with DAPI (blue). Occasional cells co-expressing
these two markers in the subventricular zone were identified in
these 1 lm optical sections. Scale bar in (a) is 10 lm and







Region % Recombination (SEM)
Cerebellar astrocytes (Bergmann glia) 70.8 (2.5)
Cortical astrocytes 52.9 (6.1)
Hippocampal astrocytes 44.3 (3.9)
Thalamic/hypothalamic astrocytes 35.1 (3.4)
Corpus callosum oligodendrocytes \1.0
Subventricular zone cells \1.0
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population of adult neural progenitor cells. While the
pattern of expression is largely similar between our two
lines, the degree of CreER expression and conse-
quently of recombination in astrocytes appears to be
slightly greater in the GFAP-CreERTMA line (compare
Figs. 2a–f and 3h, i to 5e, f). In addition, by using a less
sensitive variant of the CreER fusion protein, we
demonstrated an easily achievable dose-response
effect to tamoxifen that may be advantageous for
certain studies, such as cell-fate mapping and tumor-
igenesis. We have successfully generated spontaneous
models for diffuse astrocytomas using our GFAP-
CreERTMA line (L.M.L.C. and S.J.B., unpublished
data). Together, these various CreER mouse lines
provide novel and powerful tools for investigators to
probe normal and pathological astrocyte functions.
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